The antibody response to sporozoites of Plasmodium falciparum and the role of these antibodies in protection against malaria have not been systematically investigated. An understanding of antisporozoite antibodies in natural infection is, however, important to the development of a human malaria vaccine. In a prospective study in Thailand, an antibody response to sporozoites was observed only in individuals who developed parasitemia. Antibodies were detected against an epitope in the repeat region of the circumsporozoite (CS) protein. Current candidate sporozoite vaccines are based on CS repeat antigens. The CS antibody response was of low magnitude, peaked after detection of parasitemia, and had a serum half-life of less than 1 month. CS antibody boosting occurred in only 6% of reinfected individuals. These observations suggest that antisporozoite antibody is poorly developed under natural conditions and appears not to protect against development of malaria.
Sporozoite forms of the malaria parasite-injected by the bite of an anopheline mosquito-are the target of current efforts to produce a human malaria vaccine (14, 16) . Two candidate subunit vaccines have already reached the stage of preliminary human trials (2, 10) . The peptide constructs of both vaccines were derived from the tetrapeptide repeat region of the circumsporozoite (CS) protein, which contains an immunodominant B-cell epitope (1, 3, 8, 21, 22) . The rationale underlying development of these vaccines is that antibodies against the repeat region of the CS protein protect against sporozoite infection (13) .
Despite the remarkable technological achievements in producing these candidate sporozoite vaccines, we know relatively little about the immune response to sporozoites in naturally acquired human malaria. Although antibodies against sporozoites have been identified in sera of populations living where malaria is endemic (15, 17) , it is not known whether these antibodies have a protective role. Several recent studies have reported prevalence data on CS antibody in diverse geographical malarious areas (5, 6, 13) ; however, cross-sectional studies cannot predict whether antibodies are protective. Recently, we reported the occurrence of a CS antibody response in naturally infected Thai migrant workers (19) . That study, however, was done on patients with established malaria infection and did not show antibody kinetics during the incubation period. Assessment a.
-.. the optical density (OD) at 414 nm was determined. The mean of the three negative controls was subtracted from each value, and the mean was calculated and reported as OD units. Known positive and negative control sera were assayed in parallel with each run. Data from a negative control group were used to determine background reactivity in the ELISA and to establish a cutoff value for a positive antibody (anti-R32tet32) response 
RESULTS
Prerisk immune status. The study population was divided about evenly into malaria-naive (n = 64) and malaria-experienced (n = 71) individuals. At the start of the study, there was only marginal evidence for positive levels of CS antibodies in the malaria-experienced group (Table 1) . The mean value (0.08 OD unit) of this group fell on the test cutoff (0.08 OD unit) for reactivity. For the 18 (25%) men who had positive CS antibody levels, the median was 0.12 (range, 0.09 to 1.58) OD unit.
Antibody response to natural sporozoite exposure. During the study period, 60% of the men were infected at least once with P. falciparum. A CS antibody response was observed only in the P. falciparum-infected group. This is illustrated in Fig. 1A , which was constructed from the complete serum antibody profiles of 30 Rangers. Within the group, a positive antibody response was first detected on admission to hospital, although there appeared to be a slight rise during the preceding 10 days. CS antibodies peaked during the 10 days after admission and treatment and then rapidly declined. Antibody levels at half of the peak value were observed between 21 and 30 days, suggesting a serum half-life of less than 1 month.
There were no observed differences in the CS antibody response curves between the malaria-experienced and malaria-naive groups (time to peak, 6 to 10 days; for the peak magnitude, see Table 1 (Fig. 1C) . This observation suggested that a sporozoite inoculum sufficient to trigger a detectable immune response was invariably capable of inducing parasitemia. The observation was surprising since the 30 uninfected men and the P. falciparuîm-infected group were at equal risk.
Although most of the infected individuals showed a detectable CS antibody response, there were several hyporesponders. Of the 30 men infected for whom complete curves were available (Fig. 1A) (Fig. 2A) . Antibody boosting is defined as a secondary response in which there is at least a fourfold rise in antibody compared with a previously documented response. ABS antibody boosting was also inconsistent. There were only 5 of 16 men who had a fourfold higher IFAT peak titer on reinfection (Fig. 2B) . Four of the ABS-boosting responses were in men whose only prior malaria infection occurred during the study.
It was also apparent that the levels of CS antibody produced as a result of the first infection were not protective against subsequent infection. The mean CS antibody level in the 16 men reinfected was 0.11 OD unit (range, 0.02 to 0.42 OD unit; the value for each individual was taken from the sample point just before malaria diagnosis). This level of CS antibody was 2.3-fold higher than that observed before this group's first P. falciparum infection (P = 0.03). After reinfection, the mean peak CS antibody level was 0.42 OD unit (Table 1) . These antibody levels did not protect against development of parasitemia.
DISCUSSION
An antibody response to the immunodominant epitope of the CS protein of P. falciparum was observed in 83% of Thai Rangers with naturally acquired infections. Using a prospective study design, we observed that the peak antibody response occurred during a 10-day interval after diagnosis of patent parasitemia. A slight rise in CS antibody level was observed in the 10 days just before detection of parasitemia. Sixteen percent of parasitemic individuals had no detectable CS antibody response. In responding individuals, the magnitude of the antibody response was not influenced by previous malaria experience. The (4, 9, 18) . Whether these observations are characteristic of the human immune responses to sporozoites is not known. Our observations on CS antibody boosting, however, suggest that there are problems with T-cell function-possibly due to epitope variation or genetic restriction and possibly due to parasiteinduced immunosuppressive or immunoregulatory defects in the host (11, 20) . Additionally, the low sporozoite dose from a mosquito inoculation, and thus the small amount of CS antigen, may produce poor levels of lymphocyte priming and induction of memory cells. Development of a high-titer CS antibody response probably depends on frequent mosquito inoculation of sporozoites over a long period of time (years). Occupationally exposed groups like the Thai Rangers in this study appear not to develop protective immunity against sporozoite infection.
Evidence against a protective role for CS antibodies in natural P. jùlciparum infections was also obtained in a prospective study done in Kenya (12) . This study, which followed up adults after curative treatment, found that CS antibody levels in individuals subsequently infected were indistinguishable from those of individuals who did not develop parasitemia. There was also no apparent relationship between day of onset of parasitemia and level of CS antibody. For a sporozoite vaccine to be effective, it will have to be sufficiently immunogenic to induce antibody levels greater than those observed in this study. Furthermore, high antibody levels must be maintained in the host so that they function at the time of sporozoite inoculation-a condition that would depend on natural boosting by sporozoites or repetitive administration of a vaccine. However, the studies reported here in falciparum malaria clearly suggest that boosting of CS antibodies is poorly developed and that the levels of these antibodies may not be sufficient to confer protection in natural infection.
Although CS antibodies appear not to protect against parasitemia, they may function to modify the severity of infection by reducing the number of sporozoites which successfully invade liver cells. This may be one way of avoiding superinfection, which would be destructive to both the host and the parasite. Additionally, CS antibodies, because of their short half-life, provide an epidemiological marker for measuring active transmission in malaria-exposed populations.
